

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/162234 A1

(51) International Patent Classification:
C07F 9/6561 (2006.01) *A61P 31/18* (2006.01)
A61K 31/675 (2006.01)

(21) International Application Number:
PCT/CN2025/074583

(22) International Filing Date:
24 January 2025 (24.01.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/074517
29 January 2024 (29.01.2024) CN

(71) Applicant: **NANJING ZENSHINE PHARMACEUTICALS CO., LTD.** [CN/CN]; No.141 Longshan Road South, Building A, Jiangbei New Area, Nanjing, Jiangsu 210032 (CN).


(72) Inventors: **HAO, Xiaolin**; 637 Sandy Hook Ct., Foster City, California 94404 (US). **LEI, Yonghua**; No.141 Long-

shan Road South, Building A, Jiangbei New Area, Nanjing, Jiangsu 210032 (CN). **PENG, Zhiyuan**; No.141 Longshan Road South, Building A, Jiangbei New Area, Nanjing, Jiangsu 210032 (CN).

(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38, LinFengErLu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: PHOSPHORIC ACID DERIVATIVES AND PHARMACEUTICAL USE THEREOF



(57) Abstract: The present disclosure provides compounds having a structure set forth in formula (I), (I-1), (I-2), (I-3), (I-4), (II), (III) or (IV) the stereoisomer or a pharmaceutically acceptable salt, prodrug, or solvate thereof. Further provided are uses of the formula (I), (I-1), (I-2), (I-3), (I-4), (II), (III) or (IV), the stereoisomer or a pharmaceutically acceptable salt, prodrug, or solvate salt thereof in the prophylaxis or treatment of viral infection, especially HPV infection.

[Continued on next page]

WO 2025/162234 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))